Staff

Brickell Biotech Completes Patient Enrollment in U.S. Phase 3 Pivotal Cardigan I Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

AIM ImmunoTech Announces Positive Safety Data in Second Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a Potential Prophylaxis or Treatment for COVID-19 and Other Respiratory Viral Diseases

Antios Therapeutics Continues Building Experienced Executive Team with Appointments of Katie Laessig, M.D., as SVP, Global Regulatory Affairs and Karen Fusaro as SVP, Clinical Operations

error: Content is protected !!